Besides generics, Dr. Reddy’s has committed a lot of resources to develop its biosimilars as well as new chemical entity business. Biosimilars have been seen as a growth engine for large, capable ...

The news has been welcomed by healthcare activists and patients as a significant development ... would allow the manufacture of the generic version of the drug and ensure procurement of medicine ...

A generic version of Wegovy is not yet available in the United States. Certain patents for Wegovy will expire in several years’ time. Once that occurs, a generic version may become available in ...

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

The demand for cost-effective alternatives to biologics, which are often high-cost treatments, has spurred the development and adoption of biosimilars, presenting lucrative opportunities for ...

The Division of Policy Development in the Office of Generic Drug Policy, which was created more than a decade ago, was ...

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market. The tablets, bioequivalent to Otsuka's Jynarque, will be manufactured at ...

Sunshine Biopharma currently markets 70 generic prescription drugs in Canada ... The company is also progressing with its proprietary drug development program, which includes K1.1 mRNA for ...

The Medical - Generic Drugs industry comprises companies that ... the company is focused on accelerating the development of its complex generics portfolio. RDY is also making efforts to ensure ...

It’s unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is ...

Trump recently proposed tariffs on pharmaceutical products. Experts say this could lead to added costs, drug shortages and even a stall in research and development.